Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tarcocimab tedromer · 1 trial · 1 indication
Mean change in BCVA from Day 1 to Year 1
| Arm | Type | Description |
|---|---|---|
| Tarcocimab tedromer 5 mg (KSI-301) | EXPERIMENTAL | Intravitreal injection of tarcocimab tedromer once every 4 weeks for 4 monthly doses followed by individualized dosing every 4 to 24 weeks. |
| Tabirafusp tedromer 5 mg (KSI-501) | EXPERIMENTAL | Intravitreal injection of tabirafusp tedromer once every 4 weeks for 4 monthly doses followed by every-8-week dosing with additional individualized dosing (up to monthly dosing) |
| Aflibercept 2 mg | ACTIVE_COMPARATOR | Intravitreal injection of aflibercept once every 4 weeks for 3 monthly doses followed by every-8-week dosing |
| Name | Type | Description |
|---|---|---|
| Tarcocimab tedromer | DRUG | Intravitreal injection |
| Tabirafusp tedromer | DRUG | Intravitreal injection |
| Aflibercept | DRUG | Intravitreal injection |
Inclusion Criteria: * Active, treatment-naïve choroidal neovascularization (CNV) secondary to AMD, including subfoveal, juxtafoveal, and extrafoveal lesions, or retinal angiomatous proliferations (RAP) lesions with a CNV component that affects the central subfield, as evidenced by FA or OCT in the ...
Tarcocimab tedromer is an investigational antibody being developed for the treatment of wet age-related macular degeneration (wAMD). It is currently in Phase 3 clinical development and has not been approved by regulatory authorities.
Tarcocimab tedromer is an antibody, classified as a -mab, that is being studied for its efficacy and safety in treating wet age-related macular degeneration. The specific molecular target is not disclosed in the available information.
Tarcocimab tedromer is being developed by Kodiak Sciences Inc, a biopharmaceutical company listed on the stock exchange under the ticker symbol KOD.
Tarcocimab tedromer is currently in Phase 3 clinical development. It is an investigational drug and has not yet received approval from regulatory agencies for the treatment of wet age-related macular degeneration.
Tarcocimab tedromer is being evaluated in a Phase 3 clinical trial with the identifier NCT06556368, known as the DAYBREAK study. This randomized, double-blind, active-controlled trial compares tarcocimab tedromer and tabirafusp tedromer against aflibercept in participants with wet age-related macular degeneration.
No, tarcocimab tedromer and tabirafusp tedromer are distinct investigational drugs. Both are being studied in the same Phase 3 clinical trial (NCT06556368) for wet age-related macular degeneration, but they are separate molecules with different properties.